Schedule 13G Filing for Rani Therapeutics Holdings, Inc.

The Schedule 13G filing reports the beneficial ownership of Class A Common Stock of Rani Therapeutics Holdings, Inc. by several entities and individuals, collectively referred to as the Reporting Persons. As of October 16, 2025, the Reporting Persons collectively beneficially owned 9,825,911 shares, representing 9.99% of the issued and outstanding shares. The filing includes detailed information on the ownership structure, with Invus Public Equities, L.P. and Avicenna Life Sci Master Fund LP being the primary entities holding shares. The filing also outlines the relationships between the Reporting Persons and their respective ownership percentages. The filing is made pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934.